AR and melanoma: In contrast to the inhibitory effects of AR inhibitors on the growth of BRAFi-resistant melanoma cells, the treatment with the AR agonist dihydrotestosterone (DHT) significantly increased their proliferation (Supplementary Fig. 7e).